Startup | May 09, 2022
InxMed raises US $ 15 million in Series B+ financing
The plan is to advance innovative therapies to drug-resistant cancers
The plan is to advance innovative therapies to drug-resistant cancers
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
While Pregabalin will be manufactured at the Aurangabad facility, Iloperidone will be manufactured at the Goa facility
The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad
According to the National Institutes of Health, more than six million Americans, most age 65 or older, may have dementia caused by Alzheimer's disease, a brain disorder known to slowly destroy memory and thinking skills
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Docosanol Cream, 10% (OTC) has an estimated market size of US$60 million for twelve months ending December 2021 according to IQVIA
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
Subscribe To Our Newsletter & Stay Updated
